QC
ACRS icon

Quadrature Capital’s Aclaris Therapeutics ACRS Stock Holding History

Quadrature Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.6K Sell
10,895
-61,645
-85% -$275K ﹤0.01% 1506
2026
Q1 		$272K Buy
72,540
+14,870
+26% +$50.2K ﹤0.01% 1014
2025
Q4 		$174K Buy
57,670
+26,117
+83% +$66K ﹤0.01% 1001
2025
Q3 		$59.6K Sell
31,553
-6,697
-18% -$11.7K ﹤0.01% 943
2025
Q2 		$54.5K Sell
38,250
-1,081
-3% -$1.46K ﹤0.01% 939
2025
Q1 		$59.8K Buy
+39,331
New +$83.9K ﹤0.01% 966

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Quadrature Capital's ACRS Position: Q2 2026 in Review

Quadrature Capital reduced its Aclaris Therapeutics (ACRS) stake by 85% in Q2 2026, selling an estimated $275K and leaving 10,895 shares worth $57.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Quadrature Capital first reported a position in ACRS in Q1 2025 and has held it in 6 quarters since. The position peaked at $272K in Q1 2026. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Quadrature Capital held 10,895 shares of Aclaris Therapeutics worth $57.6K as of Q2 2026.
  • Quadrature Capital sold 61,645 Aclaris Therapeutics shares in Q2 2026, an estimated $275K.
  • Aclaris Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1506 holding.
  • Quadrature Capital first reported a position in Aclaris Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Quadrature Capital's Aclaris Therapeutics position peaked at $272K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.